13.02

2.47% -0.33

Wave Life Sciences Ltd (WVE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché WVE Giù? Forum Previsione

Precedente Chiudi:

$13.35

Aprire:

$13.42

Volume 24 ore:

2.83M

Relative Volume:

0.43

Capitalizzazione di mercato:

$2.45B

Reddito:

$42.73M

Utile/perdita netta:

$-204.38M

Rapporto P/E:

-10.74

EPS:

-1.2124

Flusso di cassa netto:

$-189.73M

1 W Prestazione:

-0.76%

1M Prestazione:

+2.68%

6M Prestazione:

+86.80%

1 anno Prestazione:

+26.78%

Intervallo 1D:

$12.58

$13.65

Intervallo di 1 settimana:

$12.58

$14.32

Portata 52W:

$5.28

$21.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Nome

Wave Life Sciences Ltd

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

617-949-2900

Indirizzo

7 STRAITS VIEW, SINGAPORE

Dipendente

317

Cinguettio

@WAVELifeSci

Prossima data di guadagno

2025-03-04

Ultimi documenti SEC

WVE's Discussions on Twitter

Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
WVE Wave Life Sciences Ltd	13.02	2.45B	42.73M	-204.38M	-189.73M	-1.2124
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-05	Iniziato	BofA Securities	Buy
2025-12-12	Reiterato	Wedbush	Outperform
2025-12-09	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-08-04	Iniziato	Canaccord Genuity	Buy
2025-07-28	Iniziato	Oppenheimer	Outperform
2025-07-16	Iniziato	Citigroup	Buy
2025-06-11	Ripresa	Raymond James	Outperform
2025-04-29	Iniziato	Cantor Fitzgerald	Overweight
2025-04-08	Iniziato	Wedbush	Outperform
2025-02-25	Iniziato	Jefferies	Buy
2024-10-16	Aggiornamento	Raymond James	Outperform → Strong Buy
2024-09-27	Ripresa	JP Morgan	Overweight
2024-09-19	Iniziato	B. Riley Securities	Buy
2024-09-09	Iniziato	JP Morgan	Overweight
2024-05-15	Iniziato	Wells Fargo	Overweight
2023-12-19	Aggiornamento	Leerink Partners	Market Perform → Outperform
2023-07-05	Iniziato	Raymond James	Outperform
2023-05-24	Downgrade	Jefferies	Buy → Hold
2020-12-15	Ripresa	H.C. Wainwright	Buy
2020-10-23	Iniziato	RBC Capital Mkts	Sector Perform
2019-12-31	Downgrade	SVB Leerink	Outperform → Mkt Perform
2019-11-01	Iniziato	Guggenheim	Buy
2019-07-15	Iniziato	Cowen	Market Perform
2019-04-17	Reiterato	H.C. Wainwright	Buy
2018-08-07	Iniziato	Stifel	Buy
2018-07-23	Iniziato	H.C. Wainwright	Buy
2018-03-19	Reiterato	Mizuho	Buy
2017-02-15	Iniziato	H.C. Wainwright	Buy
2016-11-10	Ripresa	Leerink Partners	Outperform
2015-12-07	Iniziato	JMP Securities	Mkt Outperform
2015-12-07	Iniziato	Jefferies	Buy
2015-12-07	Iniziato	Leerink Partners	Outperform
2015-12-07	Iniziato	Sun Trust Rbsn Humphrey	Buy

Mostra tutto

Wave Life Sciences Ltd Borsa (WVE) Ultime notizie

Mar 13, 2026

Assessing Wave Life Sciences (WVE) Valuation After WVE-007 Obesity Data And Cash Runway Update - simplywall.st

Mar 13, 2026

Mar 12, 2026

Discipline and Rules-Based Execution in WVE Response - Stock Traders Daily

Mar 12, 2026

Mar 11, 2026

Dynamic SXSW panel reshapes obesity treatment narrative, WAVE Life Sciences asserts - Traders Union

Mar 11, 2026

Mar 10, 2026

Canaccord Genuity Boosts Price Target for WAVE Life Sciences (WV - GuruFocus

Mar 10, 2026

WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) - Benzinga

Mar 10, 2026

WAVE Life Sciences (NASDAQ:WVE) Given New $52.00 Price Target at Canaccord Genuity Group - MarketBeat

Mar 10, 2026

Mar 09, 2026

Wave Life Sciences to present WVE-006 trial data at ATS - Investing.com Nigeria

Mar 09, 2026

Mar 08, 2026

Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval PushWhat's Changed - simplywall.st

Mar 08, 2026

Mar 07, 2026

Wave Life Sciences (WVE) Valuation Check After New RNA Editing And Obesity Trial Updates - simplywall.st

Mar 06, 2026

Wedbush Forecasts Strong Price Appreciation for WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat

Mar 06, 2026

Wave Life Sciences (WVE) Anticipates Positive Developments with WVE-007 Data - GuruFocus

Mar 06, 2026

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Sahm

Mar 06, 2026

Wave Life Sciences to present WVE-006 trial data at ATS By Investing.com - Investing.com Canada

Mar 06, 2026

Mar 05, 2026

Wave Life Sciences announces acceptance of late-breaking oral presentation on Wve-006 for alpha-1 antitrypsin deficiency at the American Thoracic Society international conference - marketscreener.com

Mar 05, 2026

Wave Life Sciences Announces Acceptance of Late-Breaking - GlobeNewswire

Mar 05, 2026

Q1 EPS Forecast for WAVE Life Sciences Raised by Analyst - MarketBeat

Mar 05, 2026

Mar 04, 2026

FY2029 Earnings Forecast for WVE Issued By HC Wainwright - MarketBeat

Mar 04, 2026

Mar 03, 2026

Wave Life Sciences Obesity Proof Of Concept Sparks Focus On Pipeline Upside - simplywall.st

Mar 03, 2026

WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 03, 2026